ANZCTR search results

Brief description of the study purpose: The study aims to evaluate whether a brief online education module can help cares of people with cancer feel more confident communicating with healthcare providers, improve their health literacy, increase their preparedness for carefiving, and support their psychological wellbeing. Who is it for? You may be eligible for this study if you are 18 years or older who provide support for someone currently receiving treatment for cancer, where the cancer diagnosis was made within the past three years. Participants must be able to read and speak English and have access to the internet and a digital device. Study details All eligible participants will be randomly assigned to one of two groups. One group will complete a 15-minute online eLearning module designed to strengthen communication and advocacy skills when interacting with the healthcare providers. The module includes interactive activities and audio-visual educational content and can be completed at the participant's own pace. The other group will continue providing care as usual and will not receive the training during the study period. All participants will complete online questionnaires at the start of the study, 2 weeks later, and 3 months later. The survey will assess factors such as communication confidence, health literacy, caregiving preparedness, psychological wellbeing, and experiences interacting with healthcare providers. Participants in the control group will receive access to the eLearning module after completing the final survey, and will not be assessed for impact of the module. It is hoped that this research will help identify effective ways to support cancer carers, enabling them to communicate more confidently with healthcare providers and improve the quality of care and support provided to people affected by cancer.

The Let’s Grow+ trial is designed to assess the efficacy, cost-effectiveness, and scalability of a mobile health intervention aimed at improving nutrition, physical activity, sleep, and reducing sedentary behaviour in toddlers. The intervention involves a 6-month mHealth program delivered via an app, including behaviour change techniques like goal setting and self-monitoring, supported by push notifications.

People living with rheumatic fever and rheumatic heart disease are often recommended to have antibiotic injections at least every 28-days over five years to reduce their risk of permanent heart damage. Our team has developed a new, less painful, way to deliver the antibiotic, called ‘SCIP’, which provides 10-weeks of protection. By partnering with Derbarl Yerrigan Health Service, we will offer SCIP to people in need of regular BPG in Perth, Western Australia, and evaluate how well it works for them, with the ultimate goal of using SCIP to reduce rheumatic heart disease morbidity. We hypothesize that SCIP will provide an acceptable alternative way for people to get their regular BPG.

When surgeons perform weight-loss sleeve gastrectomy, they remove most of the stomach to leave a narrow tube, but there is little agreement on what the ideal size and shape of the remaining stomach should be, and it is not known how much this varies between surgeons or changes over time. This study follows adults having sleeve gastrectomy with several different surgeons and uses three-dimensional CT scans of the stomach taken before surgery and again over the following five years to measure its size and shape in a standardised way. We will compare these measurements between different surgeons and within the same surgeon to see how much variation exists, and how the stomach changes over time. We will also look at whether these anatomical measurements relate to weight loss and to reflux symptoms. The aim is to define what a standard, well-constructed sleeve looks like, which could help make the operation more consistent and improve patient outcomes.

Some people who have weight-loss (sleeve gastrectomy) surgery later develop troublesome acid reflux, and when medication does not control it surgeons can offer revision surgery: repairing a hiatus hernia on its own, or repairing it and converting the stomach to a gastric bypass. This study follows adults having this revision surgery as part of their usual care and measures whether their reflux improves. Before surgery and again afterwards we compare each patient's acid-reflux test results (pH monitoring) and their reflux symptom (Visick) scores, and we record any complications, whether anti-reflux medication is restarted, and satisfaction with surgery. There is no separate control group; each participant acts as their own comparison, and we also compare the two revision approaches. We expect revision surgery to reduce both acid exposure and symptoms, which will help patients and surgeons choose between the two revision options.

The aim of this project is to support pre-service teachers’ holistic health during their final in-school teaching placement. Non-controlled trial The studies hypothesis is that by participating in physical activity and zooms the pre-service teachers may have better physical activity patterns, mental health and social support whilst on placement.

This project is piloting Shared Medical Appointments (SMAs) — group-based sessions that bring together individual clinical care, education, and peer support — for women with endometriosis at the WSIH MyHealth Integrative Medical Centre in Western Sydney. We will test this program to see how well it works and whether people find it helpful and easy to take part in. What we learn will help us create ongoing group integrative SMAs for women with endometriosis at WSIH MyHealth, including programs tailored to specific cultural groups. It will also help guide similar group programs for other women's health conditions.

This is a phase 2b, multi-centre, double-blind randomised controlled trial evaluating psilocybin-assisted psychotherapy (PAT) for methamphetamine use disorder (MAUD). One hundred and twenty treatment-seeking adults with MAUD will be randomised 1:1 to receive either PAT with a single 25 mg oral dose of psilocybin or PAT with a single 5 mg oral dose of psilocybin, with both groups receiving the same structured preparatory and integration psychotherapy. The primary outcome is the number of days of methamphetamine use in the 28 days prior to week 12 post-randomisation, assessed using Timeline Follow Back methodology and supported by urine drug testing. Secondary outcomes include methamphetamine abstinence and remission, other substance use, craving, mental health, sleep, quality of life, functional impairment, safety, acceptability, feasibility and cost-effectiveness. Participants will be followed to 52 weeks, with an optional open-label 25 mg psilocybin-assisted psychotherapy treatment offered after the week 16 assessment.

This randomised controlled trial aims to compare the effectiveness of three types of fixed orthodontic retainers in maintaining lower front tooth alignment after orthodontic treatment. Participants will receive either a CAD/CAM 0.026-inch stainless steel retainer, a CAD/CAM 0.018-inch stainless steel retainer, or a conventional multi-stranded stainless steel retainer. All participants will also receive a standard lower removable vacuum-formed retainer. The study will assess post-treatment tooth stability as the primary outcome, as well as retainer failure, periodontal health, and patient satisfaction. We expect to determine whether the CAD/CAM retainers provide similar or improved stability and clinical outcomes compared with the conventional fixed retainer.

This pilot study will compare three pain-treatment approaches in children aged 2–16 years with burn injuries: standard care with paracetamol, paracetamol plus celecoxib, and paracetamol plus ibuprofen. The study will assess whether celecoxib and ibuprofen can be used safely in these children and whether they reduce inflammation, pain and the time required for burn wounds to heal. It will also examine whether the treatments affect the need for skin grafting, scar outcomes and post-traumatic stress symptoms. We hypothesise that children receiving celecoxib or ibuprofen will have less inflammation and improved healing outcomes compared with children receiving paracetamol alone, without an unacceptable increase in adverse effects.